HNGE Hinge Health, Inc. Insider Trading

Director Gabriel Mecklenburg sells 83,334 shares ($5.0M) in 7 tranches at HNGE under scheduled 10b5-1 plan; retains 1,777,341 derivative shares.

Gabriel M.I. Mecklenburg, a Director at Hinge Health, executed 7 separate sales totaling 83,334 shares for $5,018,132.67 on 2026-06-01 at prices ranging from $55.74 to $61.68, with a blended average of $60.22. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-01, meaning it is scheduled rather than discretionary. While the non-derivative holdings reached zero post-transaction, Mecklenburg retains 1,777,341 Class B Common Stock shares in derivative holdings, representing a substantial continued stake in the company. The 30-day and 90-day price appreciation of +20.0% and +28.0% respectively provides context on recent stock momentum, though his prior sales at HNGE have shown mixed near-term outcomes (ranging from -13.4% to +22.4% over 30 days). Hinge Health reported strong fundamentals with annual revenue growth of +50.6% and net income of $35.1M in the latest quarter, though the company was unprofitable over its most recent full fiscal year, warranting continued monitoring of profitability trajectory.

HNGE: President Pursley sells 16,000 shares for $860.6K via scheduled 10b5-1 plan on 2026-05-26

James Pursley, President of Hinge Health, executed three separate sales totaling 16,000 shares for $860,605.72 on 2026-05-26 at blended average price $53.79, reducing his holdings by 2.0% to 780,223 shares post-transaction. This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-06-13, meaning the timing and volume were scheduled in advance rather than discretionary. The stock has appreciated +19.0% over the prior 30 days and +22.7% over the prior 90 days; his prior five same-ticker sales at HNGE have all been followed by positive 30-day and 90-day returns (ranging from +0.6% to +8.6% at 30 days, and +23.9% to +42.6% at 90 days). The company reported $182.3M quarterly revenue and $35.1M net income this quarter, but was unprofitable over its most recent full fiscal year despite +50.6% annual revenue growth. As a scheduled transaction under a 10b5-1 plan, this sale reflects pre-committed execution rather than a discretionary decision point.

Director Mecklenburg sells 83,333 HNGE shares for $4,482,885.17 via pre-arranged 10b5-1 plan

Gabriel M.I. Mecklenburg, a Director at Hinge Health, completed 3 separate sales totaling 83,333 shares for $4,482,885.17 on 2026-05-26, with a blended average price of $53.79. This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-12-01, making it a scheduled, non-discretionary sale. The insider retains 1,860,675 derivative Class B Common Stock shares, meaning this represents a reduction of non-derivative holdings only. At HNGE, Mecklenburg's prior 5 sales over the preceding two months showed mixed timing outcomes: two sales realized subsequent 90-day gains of +17.6% and +37.8%, one a 90-day loss of -3.7%, and two others generated gains of +35.8% and +17.7%, indicating his prior sales at this ticker generally preceded near-term price appreciation. The current stock price of $53.58 is 13.8% below the 52-week high of $62.18, though the 30-day and 90-day changes show positive momentum (+19.0% and +22.7% respectively). Company fundamentals show strong recent growth with annual revenue growth of +50.6% and latest quarterly revenue of $182,307,000.00 with net income of $35,128,000.00, though the company was unprofitable over its most recent full fiscal year.

Director Gabriel Mecklenburg converts and immediately sells all 50,000 shares for $2.75M at current price, clearing his entire position.

Director Gabriel Mecklenburg converted 50,000 shares and immediately sold his entire holdings for approximately $2.75 million on the same day, leaving him with zero remaining shares. This is his sixth sale at Hinge Health, following five prior sales dating back to early March. The timing pattern reveals a concerning disconnect: over a 90-day horizon, all five of his previous exits were poorly timed, with the stock gaining after each sale—yet over 30 days, two of those exits preceded declines, suggesting short-term volatility has occasionally rewarded his exits while longer-term trends have consistently worked against them. The current sale occurs as Hinge Health shows mixed financial signals: the company remains unprofitable on an annual basis but posted a profitable latest quarter with strong year-over-year revenue growth, and the stock trades modestly below its 52-week high after a substantial recent rally. Mecklenburg's complete exit after a series of sales that failed to time the longer-term trend raises questions about what has shifted in his perspective, particularly given the company's recent profitability inflection.

CEO Perez liquidates 150k shares worth $8.3M in two-day sprint; stock rebounding strongly but near CEO's recent exit points.

Perez Daniel Antonio, Hinge Health's CEO and co-founder, executed a full liquidation of 150,000 shares across two trading days, raising approximately $8.3 million. The trades were structured as conversions followed by immediate sales at prices near current levels, with no net change to his holdings—a pattern consistent with options exercise and systematic disposition. Notably, this contrasts sharply with his track record: over the prior year, Perez had completed five sales at this ticker, and four of those five timing decisions proved sound as the stock fell after each exit—only one prior sale was poorly timed when the stock subsequently rose. However, the current sale occurs as the stock has rallied substantially and now trades well below its recent highs, suggesting he is exiting into a period of strength. The company's fundamentals remain mixed: while the latest quarter showed net profitability and revenue is growing robustly year-over-year, the full-year earnings remain deeply negative. This is Perez's first open-market sale after extending his tenure; prior transactions were equity compensation rollovers. The sale's scale and complete liquidation, combined with his historically accurate sell timing, warrants scrutiny regarding any underlying concerns, though the stock's recent strength tempers the bearish signal.